NCT06716905View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

March 6, 2025

Primary Completion Date

July 31, 2025

Study Completion Date

December 31, 2025

Conditions
Non-alcoholic Steatohepatitis
Interventions
DRUG

ACT500 tablets

Participants will receive a single ascending oral dose of ACT500 Tablets under fasting state on the first day in Part 1

DRUG

Placebo

Participants will receive placebo matched to ACT500 Tablets.

DRUG

ACT500 tablets

Participants will receive multiple ascending oral dose of ACT500 Tablets under fasting state once daily for 7 days in Part 2.

DRUG

Placebo

Participants will receive placebo matched to ACT500 Tablets.

Trial Locations (1)

Unknown

RECRUITING

Zhongnan Hospital of Wuhan University, Wuhan

All Listed Sponsors
collaborator

Zhongnan Hospital

OTHER

lead

Xiamen Amoytop Biotech Co., Ltd.

INDUSTRY